Skip to main content

Braeburn resubmits new drug application for experimental opioid use disorder treatment

The FDA in December rejected the company's previous attempt to get the new drug candidate approved.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.